Groups
Main Sector
Investor Type
Service Provider Type
Sector Interest
Biotech Subsector
Medtech Subsector
Indication
Biotech Phase of Development
Medtech Phase of Development
Capital Structure Preference
Investment Stage Preference
Index
Countries
Reset

Artery Therapeutics Inc. United States

Artery Therapeutics is a San Francisco Bay Area based translational biotechnology company with worldwide collaborations. Artery's novel peptide library derived from Apolipoprotein E shows promising results in various animal studies for diseases such as Alzheimer's disease, Diabetes mellitus, and Acute Coronary Syndrome.

Website:
www.arterytx.com
Year Founded
2004
Main Sector
Biotech Subsector
Indication
Biotech Phase of Development
Technology Overview

Licensed peptide technologies from University of California, Berkeley, i.e. ApoE Derived ABCA1 Agonists with athero-protective, anti-diabetic actions and effects on ApoE4 associated Alzheimer’s Disease. The lead ABCA1 agonists are non-toxic, drugable candidate drugs ready to enter into IND enabling studies for phase 1 and proof of concept testing in man.

Alliance & Collaborations
Currently no Alliances or Corporate Collaborations. ARTERY has entered into several material transfer agreements with BigPharma potentially leading to collaboration deals or other deals.
Supporting Metrics or Evidence

Cogpep for Alzheimer’s Disease and Traumatic Brain Injury 90% reduction of P-Tau, 55% reduction in Amyloidb42, Increase Vglut1, apoER2, short term and long term cognition. Dipep shows antidiabetic actions (glucose reducing and insulin sensitizing) and anti-atherosclerosis effects without creating hypoglycemia. Stabilization and regression of atherosclerosis (25-40%) Weight neutral & preservation of β-cell function Lowers HbA1C

Current Financing Needs

Artery is seeking a committed pharma partner to move technology to market and beyond. Or $16M to move technology into IND enabling studies for phase 1 and proof of concept testing in man.

Current Timeline

Both Cogpep and Dipep are candidate drugs and can be in the clinic within 12 months

Current Investors

F&F

IP Status

7 cases, 37 patents, 5 issued,

Recent Milestones

Animal proof of concept studies in diabetes and Alzheimer’s disease, Has secured multiple MTA with Big Pharma Additional composition of matter patents has been filed

Management Team Highlights

Jan Johansson MD, PhD is a serial Biotech entrepreneur and has as founder and/or corporate officer helped take 3 companies’ public and raised more than $400M in private and public markets. Jan is trained as a basic scientist, practiced cardiovascular medicine for 18 years and has translational and development background with particular reference to cardiovascular technologies. Jan has lead basic research groups and lead clinical phase 1-3 programs. Jan is the inventor of more than 40 patents

Mr Jonas Johansson
Mr Jonas Johansson
Co-Founder 

Artiman Ventures

Artiman is a venture capital company founded in 2 and based in Palo Alto California. The firm is currently making investments out of its fourth $2 million fund. The firm makes seed and venture investments into firms ranging from a few hundred thousand to $5 million depending on the stage and financial requirements of the company. The firm has a preference for companies based in Silicon Valley but will consider opportunities globally and looks to make around 5 investments per year.
Website:
www.artiman.com
Investor Type
Sector Interest
Biotech Subsector
Medtech Subsector
Indication
Biotech Phase of Development
Medtech Phase of Development
Capital Structure Preference
Investment Stage Preference
Akhil Saklecha
Managing Director 

Asset Management Ventures

Asset Management Ventures is a private investment firm funded by a single LP and is based in California USA. The firm invests in seed and early-stage health technology companies. The typical investment size for seed investment ranges from $25K to $1M (usually in equity or convertible notes). For early-stage companies the firm typically co-invests with other VC firms in Series A and B financing and the investment size will depend on the company?s financial needs. The firm is geographically agnostic but prefers start-ups to be based on the West Coast. The firm is actively seeking new investment opportunities.
Website:
www.assetman.com
Investor Type
Sector Interest
Biotech Subsector
Indication
Biotech Phase of Development
Capital Structure Preference
Investment Stage Preference
Richard Simoni
Managing Partner 

Baird Venture Partners

Baird Venture Partners is the venture and expansion capital arm of Robert W. Baird & Co. The Baird Venture Partners team is based in Chicago Illinois and has around $27 million in total assets under management. In 214 Baird closed a fourth venture capital fund at $185 million. The firm is currently seeking opportunities in the life science sector and while Baird has no strict timeline to make investments the group would invest in a new firm within the next 6-9 months if a compelling opportunity was identified. The firm?s equity investments range from $3-1 million but are typically in the $8-1 million range.The firm will only consider investment into US based firms.
Website:
www.rwbaird.com
Investor Type
Sector Interest
Biotech Subsector
Indication
Biotech Phase of Development
Medtech Phase of Development
Capital Structure Preference
Investment Stage Preference
Momei Qu
Senior Associate 

Band of Angels

The Band of Angels is a funding organization that was founded in 1994 and it is based in Silicon Valley California. The organization typically provides capital to companies through three programs: The Band of Angels Acorn Fund and The Band of Angels Venture Fund. The group focuses on seed and Series A stage high-tech companies across several industries including life science space. The Band of Angels generally makes investments ranging from $3K to $75k but it often leads a syndication of $2-3million. Acorn Fund which is The Band?s third side fund and was founded in 29 generally makes investments ranging from $1k to $75k. The Band of Angels Venture Fund is a $5 million venture fund which raised in 1999 by The Band of Angels. Initial investment sizes of the fund are typically $3 and can go up to $2.5 million. The Band generally makes around 1 -2 investments per year. The group focuses on companies based in Silicon Valley but it will consider selective opportunities in Los Angles and San Diego areas. The group's portfolio includes biotechnology and medical device companies working with oncology and muscle recovery.
Website:
www.tosk.com
Investor Type
Sector Interest
Biotech Subsector
Indication
Biotech Phase of Development
Medtech Phase of Development
Capital Structure Preference
Investment Stage Preference
Brian Frenzel
Member 
Michael Bates
Member, Board of Directors 

Becton Dickinson (BD)

BD (Becton Dickinson and Company) based in Franklin Lakes NJ is a leading medical technology company that partners with customers and stakeholders to address many of the world?s most pressing and evolving health needs. Their innovative solutions are focused on improving drug delivery enhancing the diagnosis of infectious diseases and cancers supporting the management of diabetes and advancing cellular research. The firm has nearly 3 associates in 5 countries who strive to fulfill our purpose of ?Helping all people live healthy lives? by advancing the quality accessibility safety and affordability of healthcare around the world. For more information please visit www.bd.com. BD partners with companies from their formation through to commercialization including expansion of operations and channel access. BD considers a variety of engagement models including research collaborations licenses investments and acquisition when partnering with companies aligned with BD?s core businesses and new areas of strategic interest seeking opportunities from around the globe.
Website:
www.bd.com
Investor Type
Sector Interest
Biotech Subsector
Indication
Biotech Phase of Development
Medtech Phase of Development
Capital Structure Preference
Investment Stage Preference
Albert Lauritano
Director Strategic Technology Partnerships 

BioScience Managers Australia

BioScience Managers is a venture capital life science investment firm headquartered in Melbourne, Australia. The group makes equity investments from $3M-5M and anticipates about 6 new investments this year. BioScience Managers invests globally. 

BioScience Managers will invest in companies across the life science space, including therapeutics, diagnostics and medical technology. The group does not invest in service providers. BioScience Managers considers all subsectors and indications, including orphan indications. The group will consider technology either in or prepared for human clinical trials and is open to all classes of devices. BioScience Managers seeks investments in novel technology and is not looking to gain share of an existing market. 

Website:
http://www.biosciencemanagers.com/
Investor Type
Sector Interest
Biotech Subsector
Medtech Subsector
Indication
Biotech Phase of Development
Medtech Phase of Development
Capital Structure Preference
Investment Stage Preference
Jeremy Curnock Cook
Managing Director 
Amanda Gillon
Investment Analyst 
Matt McNamara
CIO 

Biosortia Pharmaceuticals United States

Biosortia has opened the door to a new frontier of fascinating compounds that have the potential to materially impact the direction of various chronic diseases.  We are dedicated to discovering new chemical entities for the management of critical chronic disease states such as cancer, neuroscience, infectious disease, and inflammatory disorders to ultimately improve the lives of others.

Value Proposition

Pharma is looking for 3 key things:

1. Novel, never seen before, chemistry from new environments to fight chronic disease

2. Higher levels of potency (nano to Pico molar) to reduce the impact of side-effects

3. New mechanisms of action to fight chronic disease in new and more effective manner

It is well known that micro-organism consortia (not macro) are one of the most biologically active and chemically diverse plant/fungi that are rich in what we call “Defense Mechanism Chemistry”.  Defense Mechanism Chemistry is key in developing drugs for cancer, infectious disease and inflammation.  The problem is no one has been able to get access to this unique chemistry at scale and have the natural products expertise to identify the unique compounds…until now.  

We will provide Pharma with new compounds, rich in “Defense Mechanism Chemistry” on a routine basis that could shorten the discovery cycle by 2-3 years and reduce the overall cost.  

Best Regards,

Kurt Dieck

President and CEO

kdieck@biosortia.com

(614) 296-7076

Website:
www.biosortia.com
Year Founded
2008
Main Sector
Biotech Subsector
Indication
Biotech Phase of Development
Technology Overview
Mobile, scalable, technology that maintains the integrity of the cell. Biosortia has proprietary methods & technologies that allow us to harvest unique single cellular micro-organism consortia never before studied and in unprecedented quantities targeting 500-1,000kg dry weight solids (DWS). Our technologies and capabilities open up this rich environment of bioactive and chemically diverse compounds for research in the pharmaceutical space for the first time ever. Biosortia’s relationship with NOAA and our Cooperative Research and Development Agreement (CRADA) with them provides Biosortia with identification and access to distinctly qualified harvest locations.
Alliance & Collaborations
(Eli Lilly, AstraZeneca, Eisai and Cubist Pharmaceuticals) with more in the pipeline.
Supporting Metrics or Evidence
Promising Early Results with big pharma (Eli Lilly, AstraZeneca, Eisai and Cubist Pharmaceuticals) with more in the pipeline. • Eli Lilly’s OIDD To date, nearly 100% of Compounds of Interest submitted into Eli Lilly’s Open Innovation Drug Discovery (OIDD) program have been accepted for evaluation…compared to an average 50-60% rejection rate on all submissions. This unprecedented achievement has recently earned Biosortia the inaugural “Collaborator of the Year” award from Lilly. In addition, due to the success in the OIDD Program, Lilly asked to join our Pharma Direct Model and test our fraction library. Initial results across simple 2 assays have produced 10 leads that they desire to follow-up in December 2014. • Big Pharma Interest As of September 30, 2014 we have 4 Big Pharma companies in our Pharma Direct Model (Eli Lilly, AstraZeneca, Cubist and Eisai) with 3 others in the pipeline in various stages of discussions.
Current Financing Needs
Capital- Biosortia has raised 2 rounds of series A Preferred Shares; November 2012 of $1.1M ($29M pre-money valuation) and September 2013 of $3.9M ($35M pre money valuation). In addition, it secured $1 million loan (2% interest) from the State of Ohio, therefore meeting our original desired capital raise of $4-5 million. The current raise is for $3-$6 million dollar to provide the runway to our first licensing agreement in Q4 2015 and drive the scaling of science capability to support the volume from our fraction libraries to be launched in Q1 of 2015.
Current Timeline
Hit rates well in excess of expectations Through our Pharma Direct Partners and 8 academic collaborators, we have over 50% of our fractions active against various therapy areas. This demonstrates both the richness of our compounds and the diversity across multiple therapy areas. With one of our Big Pharma partners alone, we have 48 active fractions/wells, with 20 showing inhibition of cancer growth from 90-99.8%. • Clear pathway to first license event in 2015 We can share with you a clear pathway to a license event in 2015. AZ, Lilly and Eisai are all on schedule to complete their R&D efforts by Q3 of 2015 that will put them in position to determine which compounds of interest they would like to license.
Recent Milestones
To date, nearly 100% of Compounds of Interest submitted into Eli Lilly’s Open Innovation Drug Discovery (OIDD) program have been accepted for evaluation…compared to an average 50-60% rejection rate on all submissions. This unprecedented achievement has recently earned Biosortia the inaugural “Collaborator of the Year” award from Lilly.
Management Team Highlights
Experienced Leadership Team & Advisors Biosortia’s leadership team has over 135 years of healthcare and life science experience with expertise in both pharmaceutical research and the micro-organism aquatic environments with the capability to provide new chemistry in a research ready format and co-develop with Pharma to pre-clinical. -Kurt D. Dieck, President and CEO - Mr. Dieck has spent 30 years in healthcare, including 18 years at Arthur Andersen where he was a global equity partner. In 2002, Kurt joined Cardinal Health, a Fortune 20 public company as a senior executive; where over his tenure he had responsibilities for Strategy, Business Development and ultimately SVP of Business Execution for the $100B pharmaceutical distribution segment. There he worked with a broad spectrum of partners, including brand pharmaceutical manufacturers, throughout the supply chain. Kurt also sits on two other healthcare related boards that are owned by Private Equity firms. -Guy T. Carter, Ph.D., Chief Scientific Officer – Dr. Carter has over 30 years of experience working in Pharmaceutical R&D, primarily in the discovery and development of microbial products. In the course of his career in the pharmaceutical industry he worked as a natural products discovery scientist and advanced through levels of scientific management to the overall leadership of the Natural Products Discovery function at Wyeth Research (later acquired by Pfizer), as well as directing other elements of the Chemical Technologies Department. Guy received a doctorate in Biochemistry from the University of Wisconsin-Madison, and then pursued marine natural products research on an NIH-sponsored post-doctoral fellowship with Kenneth Rinehart at the University of Illinois. -Haiyin He, Ph.D., VP of Research – Dr. He has more than 20 years of experience in pharmaceutical R&D, specializing in discovery of drug leads from natural products and their semi-synthetic analogs in oncology, infectious disease, and other therapeutic areas. Haiyin worked as a principle scientist III and group leader at Wyeth Research and after the merger between Pfizer and Wyeth, he continued on to work at Pfizer World Wide Medicinal Chemistry as an associate research fellow in the area of antibody-drug conjugates for cancer chemotherapy. Haiyin received a doctorate in marine natural products at Scripps Institution of Oceanography with John Faulkner, and then acquired a postdoctoral experience at Chemistry Department, Cornell University with Jon Clardy.
Dr Guy Carter
Dr Guy Carter
LinkedIn logo CSO 
Mr Kurt Dieck
Mr Kurt Dieck
LinkedIn logo President and CEO 

Biotherapeutics inc United States

BioTherapeutics Inc. (BTI) is a pre-clinical stage company developing novel small-molecule drugs to treat inflammation associated with autoimmune related disorders and type 2 diabetes (T2D). We have identified an orally-active, first-in-class top lead compound that targets a unique and novel MoA: the LANCL2 pathway. Our top lead compound has demonstrated extremely positive efficacy in mouse models of both IBD and T2D and our preliminary toxicology data has confirmed that is safe at a very high dose and as a multiple dose for 14 days.

We just closed a very well funded seed round (NIH, CIT Gap Funds, other investments) and we are now looking to raise from $3 to $5M to generate IND enabling data and start human trials.

Website:
www.biotherapeuticsinc.com
Year Founded
2008
Main Sector
Biotech Subsector
Indication
Biotech Phase of Development
Dr Adria Carbo
LinkedIn logo Scientific Director 

Boehringer Ingelheim

Boehringer Ingelheim was founded in 1885 and is based in Ingelheim am Rhein Germany. The firm invests by means of in-licensing and acquisitions and is primarily focused on respiratory diseases cardiovascular diseases metabolic diseases oncology diseases of the central nervous system and immunology. Boehringer Ingelheim also invests in veterinary medicine.

Website:
www.boehringer-ingelheim.com
Investor Type
Sector Interest
Biotech Subsector
Indication
Biotech Phase of Development
Capital Structure Preference
Investment Stage Preference
Imran Nasrullah
Director Innovation Sourcing